Company announces Phase 3 TRANSFORM study results for lisocabtagene maraleucei (Breyanzi) in relapsed/refractory B-cell lymphoma

Lisocabtagene, a CD-19 directed chimeric antigen receptor (CAR) T cell therapy, significantly improved survival and response better than standard-of-care salvage therapy with high-dose chemotherapy and transplant in patients with relapsed/refractory large-B cell lymphoma.

Biospace Inc.